Clinical trials: Cancer, Head
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University
Esophageal Cancer, Chemoradiation
Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer
The investigators designed a new preoperative chemoradiotherapy regimen to focus on the most important radiation area and hope to reduce the radiation volume and try to reduce the postoperative mortality and treatment-related…
- Conditions
- Esophageal Cancer, Chemoradiation, Surgery
- Trial name
- NCT02938195
- Testing
- radiotherapy, Surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Cancer
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003777
- Testing
- amifostine trihydrate, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
This is a randomized, open-label, active-comparator-controlled, multi-regional, three-arm, phase 3 study comparing the efficacy and safety of ivonescimab in combination with ligufalimab to pembrolizumab and of ivonescimab alone…
- Trial name
- ILLUMINE (NCT07264075)
- Testing
- Ivonescimab 10 mg/kg, Ligufalimab, Pembrolizumab (KEYTRUDA ®)
- Where
- France
- Volunteers
- 780 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT07431281
- Testing
- Sonesitatug vedotin, Rilvegostomig, Nivolumab
- Where
- 314 sites in United States, Australia and 22 more
- Volunteers
- 2,130 people
- Sponsor
- AstraZeneca
Esophagus Cancer, Diagnoses Disease
Pre-operative MRI of Esophagus Cancer
The role of MRI in the management of esophageal cancer remains unclear and poorly studied. Recent technical advances suggest that MRI may become a powerful technique for the initial assessment of esophageal cancer, but also for…
- Trial name
- STIRMCO (NCT03347630)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Dromain Clarisse
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in combination with either Nivolumab or Cetuximab in the treatment of recurrent and/or metastatic head an neck squamous cell carcinoma
- Trial name
- NCT03646461
- Testing
- Ibrutinib 560mg PO daily (Imbruvica), Cetuximab, Nivolumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Nasopharyngeal Carcinoma
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent…
- Trial name
- DIAMOND (NCT04907370)
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2)
- Where
- 12 sites in China
- Volunteers
- 532 people
- Sponsor
- Sun Yat-sen University
Oral Squamous Cell Carcinoma
Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer
The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions…
- Trial name
- NCT01587573
- Testing
- saliva collection prior to clinically driven oral biopsy
- Where
- 5 sites in United States
- Volunteers
- 370 people
- Sponsor
- PeriRx
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
Head and Neck Cancer, Radiation
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.
- Conditions
- Head and Neck Cancer, Radiation, PD-1
- Trial name
- NCT04814069
- Testing
- Tislelizumab
- Volunteers
- 38 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Oral Cancer
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer
The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients.
- Trial name
- HNC-SYSU-005 (NCT06143761)
- Testing
- PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab compared with pembrolizumab monotherapy in patients…
- Trial name
- NCT04969861
- Testing
- Bempegaldesleukin, Pembrolizumab
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 1 people
- Sponsor
- Nektar Therapeutics
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Oropharyngeal Carcinoma, De-escalation
De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations
Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed promising results, but all data…
- Trial name
- NCT04012502
- Testing
- Toxicities reduced treatment, conventional treatment
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Fudan University
Esophageal Stenosis, Deglutition Disorders
Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis
Management of pharyngoesophageal stenosis (PES) in patients after head and neck cancer (HNC) treatment remains a challenge. There are some cases of strictures refractory to dilation sessions.
- Conditions
- Esophageal Stenosis, Deglutition Disorders, Head and Neck Neoplasms, Esophageal Neoplasms
- Trial name
- NCT03540953
- Testing
- Endoscopic injection of Mitomycin C
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Fauze Maluf Filho
Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections
Modified Vaccinia Ankara (MVA) Vaccine Study
This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).
- Trial name
- NCT01256853
- Testing
- MVA Vaccine
- Where
- Hong Kong
- Volunteers
- 18 people
- Sponsor
- Chinese University of Hong Kong
Squamous Cell Carcinoma of Head and Neck
Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
To determine the outcomes of patients with specific head and neck cancer after undergoing radiation therapy with atezolizumab followed by surgery then radiation with or without chemotherapy according to national guidelines.
- Trial name
- NCT05053737
- Testing
- Atezolizumab, Stereotactic Body Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with…
- Trial name
- NCT06892431
- Testing
- Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine
- Volunteers
- 150 people
- Sponsor
- Shanghai JMT-Bio Inc.
Lung Cancer
Personalized Sequence for Thoracic, Esophageal, and H&N Cancer
The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly.
- Trial name
- NCT02299622
- Testing
- Genetic test
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.